PT Bio Farma (Persero)

What PT Bio Farma (Persero) does

PT Bio Farma (Persero) is an Indonesian company headquartered in Bandung, West Java, operating under the "(Persero)" designation that in Indonesia identifies state-owned enterprises (Badan Usaha Milik Negara). The company name "Bio Farma" combined with its location in Indonesia's established West Java pharmaceutical corridor and the state-owned corporate form indicates a positioning in the domestic biological/pharmaceutical sector, plausibly including biologics manufacturing, vaccine production, or related life-science activities serving Indonesian public health and commercial markets. The firm employs 87 people according to the available firmographic data, suggesting either a specialized single-site operation or a sub-entity within a larger group structure that is not disclosed in the source.

Direct extraction of product portfolio, underlying technology platform, customer base, and revenue mechanics is not possible from the supplied input. The company's public website (bio-farma.com) was captured only as a verification/loading page ("One moment, please..." / "Loader" / "Please wait while your request is being verified..."), and the structured enrichment fields — including products and services, technology stack, pricing, revenue, customer segments, leadership, partnerships, certifications, and operating geographies — are returned empty or marked as not extractable. Consequently, the business model, go-to-motion, and contract/pricing mechanics cannot be characterized from the available evidence beyond the structural inferences drawn from the corporate name and "(Persero)" state-owned designation.

Name

PT Bio Farma (Persero)

Website

https://bio-farma.com

Company type

Private

Headcount range

51–100 employees

Short description

PT Bio Farma (Persero) is an Indonesian state-owned enterprise ("Persero") headquartered in Bandung, West Java, operating in the biological/pharmaceutical sector with 87 employees. Its specific product lines, customers, and revenue mechanics are not disclosed in the available source data.

Ownership category

akta.pro rank

Product category

Pharmaceuticals

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development) (HLAAAIAD)

Keywords

• Biopharmaceutical products
• Vaccine manufacturing
• Biological medicines
• Pharmaceutical production
• Biotechnology solutions

GTM type

B2B

Offering type

Services

Cost components

Others

Core offering

Core offering details cannot be determined from the provided source data. The company's website and linked source material contained only a verification/loading page with no substantive product or service information. The company name "Bio Farma" suggests a biopharmaceutical orientation, but no specific products or services are evidenced in the input.

Differentiator

Problem solved

Functional benefit

Products and services

• Information not available in source data

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves1 record

Direct peers

• Novavax: US-based vaccine developer using recombinant nanoparticle technology, with COVID-19, influenza, and malaria candidates. Comparable as a vaccine-platform company targeting emerging-market supply through partnerships and licensing arrangements.
• PT Kimia Farma: Indonesian state-owned pharmaceutical company producing and distributing pharmaceuticals and healthcare products. Closest domestic comparable to PT Bio Farma as a fellow Persero in Indonesia's state pharmaceutical ecosystem, serving overlapping public-sector channels.
• BioNTech: German biotechnology company that developed mRNA COVID-19 vaccines in partnership with Pfizer. Comparable to PT Bio Farma as a biologics-focused developer with growing pipeline beyond core products, including malaria and tuberculosis vaccines targeting emerging markets.
• Sinovac Biotech: Chinese vaccine manufacturer specializing in inactivated vaccines including COVID-19, hepatitis, and influenza. Directly comparable to PT Bio Farma as a regional, emerging-market focused vaccine producer targeting both domestic and international public-health tenders.
• Bharat Biotech: Indian vaccine manufacturer producing a wide portfolio including COVID-19, rotavirus, and typhoid vaccines. Comparable to PT Bio Farma as an emerging-market vaccine innovator with strong domestic procurement and growing international footprint.
• Moderna: US-based mRNA vaccine and therapeutics company with applications across infectious diseases, oncology, and rare diseases. Comparable to PT Bio Farma as a synthetic biology/mRNA-platform vaccine developer pursuing emerging-market partnerships.
• Serum Institute of India: World's largest vaccine manufacturer by number of doses produced, focused on affordable vaccines for emerging markets. Comparable to PT Bio Farma as a high-volume, cost-efficient vaccine producer serving public-sector immunization programs.
• Sinopharm (China National Biotec Group): State-owned Chinese pharmaceutical conglomerate producing vaccines and biologics. Comparable to PT Bio Farma as a state-backed biologics manufacturer with significant scale and government procurement as a primary revenue channel.

Broad incumbents

• Sanofi Pasteur: Global vaccine division of Sanofi, producing a wide range of pediatric and adult vaccines. Comparable as a broad incumbent in the vaccine industry with overlapping product categories (polio, influenza, pediatric combination vaccines) that compete for the same global immunization tenders.
• GSK (Vaccines): Global pharmaceutical company with a major vaccines franchise covering hepatitis, rotavirus, meningitis, and HPV. Comparable as a broad incumbent competing in the same immunization and biologics categories targeted by PT Bio Farma.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat2 records

Key highlights3 records

Customer concentration

• LinkedInlinkedin.com/company/pt-bio-farma-persero-

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PT Bio Farma (Persero)